Are we over-treating with checkpoint inhibitors?

Anti-PD-1 antibodies offer potentially life-saving treatment for some cancer patients, but their chronic administration generates high and ever-increasing costs. Despite licensing for long-term use, optimal treatment duration is unknown. We challenge the need for long-term treatment duration, using...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Br J Cancer
Autors principals: Danson, Sarah, Hook, Jane, Marshall, Helen, Smith, Alexandra, Bell, Sue, Rodwell, Simon, Corrie, Pippa
Format: Artigo
Idioma:Inglês
Publicat: Nature Publishing Group UK 2019
Matèries:
Comment
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6889152/
https://ncbi.nlm.nih.gov/pubmed/31527686
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41416-019-0570-y
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars